Key Takeaways
- CRISPR Therapeutics received ARK’s largest investment with 112,815 shares worth approximately $5.63M distributed between ARKK and ARKG funds
- PayPay Corp saw ARK deploy 275,000 shares valued at roughly $4.4M via the ARKF fintech-focused ETF
- Additional acquisitions included GeneDx (approximately $4.43M) and Tempus AI (around $991K)
- ARK divested from Teradyne (roughly $3.3M) and Ionis Pharmaceuticals (approximately $3.26M)
- The firm also scaled back exposure to 10x Genomics and Circle Internet Group
Cathie Wood’s ARK Invest executed more than $10 million worth of stock purchases on March 12, 2026, while simultaneously trimming multiple portfolio holdings, based on the investment firm’s public trading records.
The most substantial acquisition involved CRISPR Therapeutics. ARK accumulated 112,815 shares distributed across two exchange-traded funds — the ARK Innovation ETF and the ARK Genomic Revolution ETF — representing a combined investment of approximately $5.63 million.
CRISPR Therapeutics specializes in gene-editing biotechnology. This investment reinforces ARK’s strategic commitment to genomic medicine’s future growth prospects.
The second-largest transaction targeted PayPay Corp, a digital payments platform. ARK secured 275,000 shares via its ARK Fintech Innovation ETF, totaling approximately $4.4 million.
PayPay Corp experienced a 13.50% stock price increase during the trading session. This acquisition expands ARK’s strategic positioning within fintech and digital payment infrastructure.
ARK simultaneously increased stakes in two additional companies. The firm obtained 52,075 shares of GeneDx, which specializes in genomic diagnostics, representing roughly $4.43 million. Additionally, ARK acquired 18,820 shares of Tempus AI, an artificial intelligence healthcare data platform, valued at approximately $991,000.
ARK’s Divestment Strategy
Regarding sales activity, ARK divested 10,919 shares of Teradyne, which manufactures semiconductor testing equipment, through the ARK Innovation ETF for approximately $3.3 million. Teradyne’s stock price declined 5.09% during the session.
This divestment represents a continuation of recent activity. ARK has systematically decreased its Teradyne allocation across multiple trading days.
ARK additionally offloaded 43,533 shares of Ionis Pharmaceuticals via its ARKG ETF, valued at roughly $3.26 million. Ionis experienced a 3.28% stock price decrease.
The Ionis divestment aligns with ARK’s broader strategy of reducing exposure to the RNA-based pharmaceutical developer.
ARK reduced two additional positions on a smaller scale. The firm sold 18,392 shares of 10x Genomics, which develops gene expression technology, for approximately $376,000 split between ARKK and ARKG.
Additionally, ARK divested 11,194 shares of Circle Internet Group, a blockchain payments and stablecoin company, through ARKK for roughly $1.26 million.
Wall Street’s Perspective
Wall Street analysts have assigned “Strong Buy” ratings to both GeneDx and Ionis Pharmaceuticals. GeneDx demonstrates the most significant upside potential among these securities, approaching 100%.
CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics each maintain “Moderate Buy” consensus ratings from the analyst community. PayPay Corp currently carries a “Hold” rating.
ARK executed an additional minor transaction, purchasing 54,736 shares of Canton Strategic Holdings via its ARKF ETF, representing approximately $254,522.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
